2020
Ponatinib is a potential therapeutic approach for malignant pleural mesothelioma
Yang YW, Marrufo A, Chase J, Woodard GA, Jablons DM, Lemjabbar-Alaoui H. Ponatinib is a potential therapeutic approach for malignant pleural mesothelioma. Experimental Lung Research 2020, 47: 9-25. PMID: 33107354, DOI: 10.1080/01902148.2020.1836691.Peer-Reviewed Original ResearchConceptsMalignant pleural mesotheliomaPonatinib treatmentPleural mesotheliomaMPM linesTherapeutic approachesPotential therapeutic approachExpression levelsNew therapeutic strategiesHuman MPM cellsMPM therapyPSTAT5 levelsWestern blot analysisMPM patientsMPM treatmentDeadly malignancyLevels of γH2AXPotential utilityTherapeutic strategiesTumor growthMPM cellsPathway inhibitionTumor modelPonatinibActivation of AblTumor samplesSurgery for pleural mesothelioma, when it is indicated and why: arguments against surgery for malignant pleural mesothelioma
Woodard GA, Jablons DM. Surgery for pleural mesothelioma, when it is indicated and why: arguments against surgery for malignant pleural mesothelioma. Translational Lung Cancer Research 2020, 9: s86-s91. PMID: 32206574, PMCID: PMC7082252, DOI: 10.21037/tlcr.2020.01.08.Peer-Reviewed Original ResearchMalignant pleural mesotheliomaExtrapleural pneumonectomyPleural mesotheliomaSurvival timePleurectomy decorticationSurgical resectionPatient selectionRetrospective single-institution reviewHigh perioperative mortality rateLonger overall survival timeLimited disease burdenMajor surgical resectionRadiation therapy trialsRadical Surgery trialPerioperative mortality rateSingle-institution reviewOverall survival timeShorter survival timeBiased patient selectionLonger survival timeElevated CRPAdvanced diseaseElevated plateletNodal diseaseMPM patients
2018
Scientific Advances and New Frontiers in Mesothelioma Therapeutics
Mutti L, Peikert T, Robinson BWS, Scherpereel A, Tsao AS, de Perrot M, Woodard GA, Jablons DM, Wiens J, Hirsch FR, Yang H, Carbone M, Thomas A, Hassan R. Scientific Advances and New Frontiers in Mesothelioma Therapeutics. Journal Of Thoracic Oncology 2018, 13: 1269-1283. PMID: 29966799, PMCID: PMC6643278, DOI: 10.1016/j.jtho.2018.06.011.Peer-Reviewed Original Research
2017
Drug development against the hippo pathway in mesothelioma
Woodard GA, Yang YL, You L, Jablons DM. Drug development against the hippo pathway in mesothelioma. Translational Lung Cancer Research 2017, 6: 335-342. PMID: 28713678, PMCID: PMC5504108, DOI: 10.21037/tlcr.2017.06.02.Peer-Reviewed Original ResearchYAP/TEADCell pathwaysCell contact inhibitionStem cell populationCancer stem cell populationStem cell pathwaysTumor suppressor geneDownstream YAPHippo pathwaySuppressor geneContact inhibitionYAP inhibitorConventional cytotoxic drugsCell populationsMalignant pleural mesotheliomaPathwayDrug developmentTumor resistanceUltimate targetTEADGenesOncogeneYAPEffective chemotherapy drugsChemotherapy drugs
2016
Whole exome and targeted deep sequencing identify genome-wide allelic loss and frequent SETDB1 mutations in malignant pleural mesotheliomas
Kang HC, Kim HK, Lee S, Mendez P, Kim JW, Woodard G, Yoon JH, Jen KY, Fang LT, Jones K, Jablons DM, Kim IJ. Whole exome and targeted deep sequencing identify genome-wide allelic loss and frequent SETDB1 mutations in malignant pleural mesotheliomas. Oncotarget 2016, 7: 8321-8331. PMID: 26824986, PMCID: PMC4884995, DOI: 10.18632/oncotarget.7032.Peer-Reviewed Original ResearchMeSH KeywordsBlotting, WesternExomeFemaleGenome, HumanHigh-Throughput Nucleotide SequencingHistone-Lysine N-MethyltransferaseHumansImmunoenzyme TechniquesLoss of HeterozygosityLung NeoplasmsMesotheliomaMesothelioma, MalignantMiddle AgedMutationPleural NeoplasmsPrognosisProtein MethyltransferasesReal-Time Polymerase Chain ReactionReverse Transcriptase Polymerase Chain ReactionRNA, MessengerSurvival RateConceptsMalignant pleural mesotheliomaPrimary cancerPleural mesotheliomaGenetic mechanismsDeep sequencingAdditional primary cancersMultiple primary cancersPrimary lung cancerPrimary cancer developmentAllelic lossNew genetic mechanismWhole-exome sequencingDistinct genomic alterationsMPM patientsRare malignancyPerineural invasionPoor prognosisTherapeutic optionsLung cancerLoss of heterozygosityTP53 mutationsCancer developmentPatientsExome sequencingCancer